|Bid||10,526.00 x 0|
|Ask||10,524.00 x 0|
|Day's range||10,308.00 - 10,578.00|
|52-week range||7,870.00 - 11,000.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||130.68|
|Forward dividend & yield||2.10 (2.04%)|
|Ex-dividend date||24 Feb 2022|
|1y target est||N/A|
WILMINGTON, Del., May 27, 2022--The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).
WILMINGTON, Del., May 23, 2022--AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2